Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Loading...
Embargo End Date
ICR Authors
Authors
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Iglesias Docampo, LC
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Jayaprakash, V
Wei, L
Ferris, RL
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Iglesias Docampo, LC
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Jayaprakash, V
Wei, L
Ferris, RL
Document Type
Journal Article
Date
2022-03-04
Date Accepted
2021-11-30
Abstract
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
Citation
ONCOLOGIST, 2022, 27 (2), pp. E194 - E198 (5)
Source Title
Publisher
OXFORD UNIV PRESS
ISSN
1083-7159
eISSN
1549-490X
1549-490X
1549-490X
Research Team
Targeted Therapy